PROMISE Criteria / miTNM Staging (PSMA-PET)
1.0.0Builds a standardized PROMISE molecular-imaging TNM (miTNM) stage from PSMA-PET findings. Select miT, miN, and miM (including bone-pattern subtypes) to generate the composite stage string, plain-language interpretation, and management-oriented notes aligned with PROMISE V2 / EAU-EANM reporting.
Also searched as: prostate cancer · nuclear medicine · Eiber · EANM · prostate
Information
Incomplete input
- Please provide: miT (local tumor), miN (pelvic nodes), miM (distant metastasis).
How this tool works
PROMISE (Prostate Cancer Molecular Imaging Standardized Evaluation) defines miTNM categories for whole-body PSMA-ligand PET reporting (Eiber et al. 2018; updated PROMISE V2, Seifert et al. 2023). Local tumor (miT), pelvic nodes (miN0–2 by number of pelvic regions), and distant disease (miM0 / miM1a nodes / miM1b bone with uni|oligo|diss|dmi patterns / miM1c visceral) mirror pathologic TNM while remaining PET-specific. PROMISE V2 also integrates PRIMARY score for the intact gland and a PSMA-expression score (not entered in this calculator).
References
- Eiber M et al. PROMISE: proposed miTNM classification. J Nucl Med. 2018;59(3):469–478
- Seifert R et al. PROMISE V2 framework. Eur Urol. 2023;83(5):405–412
- PROMISE-PET official site (pocket card & ePROMISE)
- Fendler WP et al. PSMA PET/CT joint EANM/SNMMI procedure guideline. 2023
Implemented from the cited published sources. Educational use only; confirm against current guidelines before clinical use.
Clinical questions that use this
Vetting guides that reach for this tool.
Related calculators
Same subspecialty, overlapping subject matter.